COMPARING EFFICACY OF TRELAGLIPTIN VERUS SITAGLIPTIN IN PATIENTS WITH INADEQUATELY CONTROLLED TYPE II DIABETES ON METFORMIN ALONE

Abstract

Objective: The purpose of the research is the comparison of efficacy of trelagliptin versus sitagliptin in patients with inadequately controlled type II diabetes on metformin alone

Study Design: Randomized Control Trial

Study Duration: 06 months from Oct 2024-March 2025

Study Place: Department of Medicine, CMH Lahore

Methods: A randomized, parallel, open-label, prospective study was conducted to compare the efficacy and safety of once-weekly trelagliptin versus once-daily sitagliptin in type II diabetes patients inadequately controlled on metformin. A total of 120 participants were randomized equally into two groups. Primary outcome was change in HbA1c after 12 weeks; secondary outcomes included FPG, PPG, body weight, and adverse events. Data were analyzed using SPSS v26, with p<0.05 as significant.

Results: In this 12-week study of 120 patients with type II diabetes, both trelagliptin and sitagliptin significantly improved HbA1c and glucose levels. Trelagliptin showed a slightly greater HbA1c reduction (-1.21% vs. -1.08%, p=0.048) and higher achievement of HbA1c <7% (61.7% vs. 50%, p=0.042). Both drugs were weight-neutral, well tolerated, and caused only mild gastrointestinal side effects, with no severe hypoglycemia or organ dysfunction observed

Conclusion: Both trelagliptin and sitagliptin had significant beneficial glycemic control when added to metformin in patients with inadequately controlled type II diabetes. Their safety and tolerance profiles were similar. Sitagliptin has long-term evidence and cardiovascular safety, whereas trelagliptin's once weekly dosing may enhance patient adherence.